Teva Pharmaceutical Industries Ltd (TEVA) Position Lowered by Heritage Investors Management Corp
Heritage Investors Management Corp cut its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 3.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 81,506 shares of the company’s stock after selling 3,125 shares during the period. Heritage Investors Management Corp’s holdings in Teva Pharmaceutical Industries were worth $1,278,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in TEVA. FMR LLC boosted its position in Teva Pharmaceutical Industries by 44.0% in the 4th quarter. FMR LLC now owns 35,248,665 shares of the company’s stock valued at $543,534,000 after buying an additional 10,766,729 shares during the period. Brahman Capital Corp. boosted its position in Teva Pharmaceutical Industries by 67.3% in the 4th quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock valued at $188,866,000 after buying an additional 4,925,245 shares during the period. Polaris Capital Management LLC boosted its position in Teva Pharmaceutical Industries by 4.4% in the 4th quarter. Polaris Capital Management LLC now owns 10,342,980 shares of the company’s stock valued at $159,489,000 after buying an additional 431,942 shares during the period. Norges Bank purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at about $146,130,000. Finally, Northern Trust Corp boosted its position in Teva Pharmaceutical Industries by 2.7% in the 4th quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock valued at $103,125,000 after buying an additional 175,173 shares during the period. 67.26% of the stock is owned by hedge funds and other institutional investors.
NYSE:TEVA opened at $14.55 on Wednesday. Teva Pharmaceutical Industries Ltd has a one year low of $14.50 and a one year high of $25.96. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.96 and a quick ratio of 0.63. The stock has a market capitalization of $15.29 billion, a PE ratio of 5.20, a price-to-earnings-growth ratio of 2.91 and a beta of 1.33.
Several equities research analysts have issued reports on TEVA shares. HSBC set a $12.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Tuesday, February 5th. ValuEngine cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Maxim Group reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 14th. Credit Suisse Group lowered their price objective on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, February 14th. Finally, UBS Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, March 7th. They issued a “buy” rating and a $22.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $21.05.
In related news, VP Richard Daniell sold 2,098 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $35,414.24. Following the completion of the transaction, the vice president now owns 2,098 shares in the company, valued at approximately $35,414.24. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Notaristefani Carlo De sold 5,041 shares of the business’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $17.88, for a total transaction of $90,133.08. Following the transaction, the vice president now owns 17,162 shares of the company’s stock, valued at approximately $306,856.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,691 shares of company stock valued at $283,458. 0.43% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Position Lowered by Heritage Investors Management Corp” was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-ltd-teva-position-lowered-by-heritage-investors-management-corp/2952802.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Yield Curve
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.